An Immunogenicity and Safety Evaluation of Menactra(R) (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel(R) at 15 to 18 Months of Age.

Trial Profile

An Immunogenicity and Safety Evaluation of Menactra(R) (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel(R) at 15 to 18 Months of Age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hib-DTaP-poliovirus vaccine
  • Indications Diphtheria; Haemophilus infections; Meningitis; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 14 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 17 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 15 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top